Canine Cancer Screening Market: Selling A Test For A Dog That Looks Perfectly Well

Between 2020 and 2025 this field went from research curiosity to commercial reality and then discovered how hard the commercial part is. Pandemic-era pet acquisition pushed veterinary spending sharply higher, the first cell-free DNA screening panels launched, and adoption ran well below every launch forecast. A 13.4% historical CAGR combines genuine product arrival with a distribution problem nobody solved.
Three mechanisms carry the 14.5% base case. Breed-targeted screening is the first, since lifetime cancer risk in some pedigrees runs above half and gives veterinarians a defensible reason to recommend testing at a specific age. Pet insurance expansion is the second, as wellness riders increasingly cover screening panels outright. And corporate veterinary group consolidation is the third, because a protocol adopted centrally reaches thousands of clinics at once rather than one at a time.
The 15.8% bull case rests on a major insurer adding cancer screening to standard wellness cover, which would remove the owner payment decision entirely and change adoption overnight. The 13.2% bear case is false positive experience: a run of healthy dogs sent for expensive imaging that finds nothing would damage veterinarian confidence faster than any marketing budget could rebuild it.